RPCEC00000396尚未招募未知
Intranasal use of recombinant human interferon alfa-2b in the treatment of asymptomatic and mild symptomatic low-risk patients with suspected and confirmed COVID-19. (COVID-19) - NASALFERON-SNS
Center for Genetic Engineering and Biotechnology (CIGB)0 个研究点目标入组 200 人开始时间: 2021年11月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 10 years 至 80 years（—）
- 性别
- All
入选标准
- •1. Low risk suspect, mild symptomatic, with positive antigen test.
- •2. Confirmed low risk, asymptomatic and mild symptomatic, with positive PCR.
- •3. Voluntariness of the patient or legal representative.
排除标准
- •1. Individuals confirmed COVID-19 and classified as medium and high risk.
- •2. Individuals with hypersensitivity to thiomersal (thimerosal).
- •3. Individuals with hypersensitivity to interferon alpha
研究者
相似试验
暂停
2 期
asalferon in COVID-19COVID-19SARS-CoV-2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsNidovirales InfectionsBetacoronavirusRPCEC00000399Center for Genetic Engineering and Biotechnology (CIGB)128
已完成
1 期
OLIVO StudyProphylaxis of SARS-CoV-2 infectionCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsNidovirales InfectionsBetacoronavirusRPCEC00000337Center for Genetic Engineering and Biotechnology (CIGB), in Havana80
已完成
2 期
Recombinant interferon alpha-2b in paranoid schizophrenia.RPCEC00000067Center for Genetic Engineering and Biotechnology (CIGB), Havana City.60
尚未招募
2 期
asal recombinant human interferon alfa-2b in ARIRespiratory Tract InfectionsRespiratory Tract DiseasesInfectionsacute respiratory infectionRPCEC00000412Center for Genetic Engineering and Biotechnology (CIGB)608
尚未招募
2 期
asalferon in ARIAcute respiratory infection (ARI)Respiratory Tract InfectionsRespiratory Tract DiseasesInfectionsRPCEC00000407Center for Genetic Engineering and Biotechnology (CIGB)495